Physician profile
Keith Thomae
NPI 1184679409
$22,870.95
in general payments reported to CMS, 2019-2025
30 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,807 · 2020: $184 · 2021: $522 · 2022: $3,036 · 2023: $745 · 2024: $2,035 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $12K · Travel and Lodging: $3,653 · Food and Beverage: $2,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $11,539.04 |
| Travel and Lodging | $3,652.97 |
| Food and Beverage | $2,130.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,980.81 | 2025 | |
| Tela Bio, INC. | $4,724.04 | 2019-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Endogastric Solutions, INC | $2,012.77 | 2019-2024 | Esophyx |
| Kerecis Limited | $384.22 | 2020-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Tas Medical, INC. | $335.92 | 2024 | |
| Biotissue Holdings INC. | $163.26 | 2025 | |
| Novartis Pharmaceuticals Corporation | $160.27 | 2022-2023 | |
| Davol INC. | $135.40 | 2025 | Phasix Mesh |
| Solventum Corporation | $116.40 | 2025 | V.A.C. Veraflo, Prevena, V.A.C.Ulta |
| Innovation Technologies INC | $101.62 | 2023 | Irrisept |
| Medtronic, INC. | $94.71 | 2025 | Nim Vital |
| Amneal Pharmaceuticals LLC | $84.65 | 2022-2023 | Rytary |
| Endologix LLC | $77.65 | 2021 | |
| Kci USA, INC. | $75.65 | 2019-2022 | |
| Covidien Lp | $68.71 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $40.53 | 2022-2023 | Qulipta |
| Boston Scientific Corporation | $38.67 | 2020-2021 | |
| Innocoll Pharmaceuticals Limited | $33.68 | 2021-2022 | |
| Acera Surgical, INC. | $32.95 | 2021 | |
| Amgen INC. | $31.08 | 2019-2022 | |
| Argenx US, INC. | $25.23 | 2022 | |
| Clovis Oncology, INC. | $23.65 | 2019 | |
| Avion Pharmaceuticals | $22.50 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.83 | 2022 | |
| Midsouth Orthopedics INC. | $19.71 | 2022 | |
| Celgene Corporation | $16.76 | 2019 | |
| Aesculap, INC. | $15.99 | 2019 | |
| Shire North American Group INC | $12.53 | 2019 | |
| Acell, INC. | $12.14 | 2020 | |
| Corium, LLC | $9.62 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Thomae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.